An intervention programme for the management of multidrug-resistant tuberculosis in France

International Journal of Antimicrobial Agents

Volumn 29, Issue 4, 2007, Pages 434-439

  Uffredi, Marie Laure ^a   Truffot Pernot, Chantal ^a   Dautzenberg, Bertrand ^a   Renard, Muriel ^a   Jarlier, Vincent ^a   Robert, Jérôme ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Isoniazid; Outcome; Resistance; Rifampicin; Tuberculosis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; KANAMYCIN; OFLOXACIN; PYRAZINAMIDE; SPARFLOXACIN; STREPTOMYCIN; THIOACETAZONE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SCREENING; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FRANCE; HAZARD ASSESSMENT; HEALTH PROGRAM; HEARING LOSS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INTERVENTION STUDY; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LUNG LOBECTOMY; LUNG RESECTION; LYMPHADENECTOMY; MALE; MICROBIOLOGY; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NEUROLOGIC DISEASE; OPTIC NEURITIS; OUTCOME ASSESSMENT; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN ALLERGY; SKIN MANIFESTATION; THORAX SURGERY; TREATMENT DURATION; TREATMENT PLANNING; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; FRANCE; HUMANS; MICROBIAL SENSITIVITY TESTS; MULTIVARIATE ANALYSIS; NATIONAL HEALTH PROGRAMS; SURVIVAL RATE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 33847343351     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.11.023     Document Type: Article

References (22)

1. Robert J., Trystram D., Truffot-Pernot C., and Jarlier V. Multidrug-resistant tuberculosis in France: eight years of surveillance (1992-1999). Eur Respir J 22 (2003) 833-837
2. Flament-Saillour M., Robert J., Jarlier V., and Grosset J. Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med 160 (1999) 587-593
3. Goble M., Iseman M.D., Madsen L.A., Waite D., Ackerson L., and Horsburgh C.R. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 328 (1993) 527-532
4. Park M.M., Schluger N.W., Cohen H., and Rom W.N. Outcome of MDR-TB patients, 1983-1993, prolonged survival with appropriate therapy. Am J Respir Crit Care Med 153 (1996) 317-324
5. Suarez P., Floyd K., Portocarrero J., et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 359 (2002) 1980-1989
6. Tahaoglu K., Torun T., Sevim T., et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 345 (2001) 170-174
7. World Health Organization. Global tuberculosis control. WHO Report 2003. WHO/CDS/TB/2003.316. http://www.who.int/gtb/publications/globrep/contents.html [accessed 15 December 2006].
8. Stop TB Working Group on DOTS-Plus for MDR-TB. A prioritised agenda for DOTS-Plus for multidrug-resistant tuberculosis (MDR-TB). Int J Tuberc Lung Dis 2003;7:410-14.
9. Crofton J, Chauley P, Maher D. Guidelines for the management of drug-resistant tuberculosis. WHO/TB/96.210 (Rev 1) ed. Geneva, Switzerland: World Health Organization; 1997.
10. Canetti G., Rist N., and Grosset J. Mesure de la sensibilité du bacille tuberculeux aux drogues antibacillaires par la méthode des proportions. Rev Tuberc Pneumol (Paris) 27 (1963) 217-272
11. Heifets L. Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 2002;51:11-12.
12. World Health Organization, International Union Against Tuberculosis and Lung Disease, Royal Netherlands Tuberculosis Association. Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 2001;5: 213-15.
13. Rossau R., Traore H., De Beenhouwer H., et al. Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrob Agents Chemother 41 (1997) 2093-2098
14. Lemaitre N., Sougakoff W., Truffot-Pernot C., and Jarlier V. Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob Agents Chemother 43 (1999) 1761-1763
15. Chan D.E., Laurel V., Strand M.J., et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 169 (2004) 1103-1109
16. Mitnick C., Bayona J., Palacios E., et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 348 (2003) 119-128
17. Narita M., Alonso P., Lauzardo M., Hollender E., Pitchenik A., and Ashkin D. Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997. Chest 120 (2001) 343-348
18. Lubasch A., Erbes R., Mauch H., and Lode H. Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy. Eur Respir J 17 (2001) 641-646
19. Singla R., Gupta S., Gupta R., and Arora V. Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients: preliminary results. Int J Tuberc Lung Dis 5 (2001) 559-563
20. Frieden T.R., Sterling T., Pablos-Mendez A., Kilburn J.O., Cauthen G.M., and Dooley S.W. The emergence of drug-resistant tuberculosis in New York city. N Engl J Med 328 (1993) 521-526
21. Pablos-Méndez A., Sterling T.R., and Frieden T.R. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. J Am Med Assoc 276 (1996) 1223-1228
22. Sterling T., Lehmann H., and Frieden T. Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ 326 (2003) 574-579